{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:03:56Z","timestamp":1778011436902,"version":"3.51.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This narrative review examines the therapeutic potential of rituximab, a monoclonal antibody targeting CD20 antigens, for treating connective tissue disease-associated interstitial lung disease. It outlines how rituximab offers a promising therapeutic option, particularly for patients who exhibit limited responses to standard therapies like glucocorticoids and immunosuppressive agents. Rituximab\u2019s mechanism of action, involving B lymphocyte depletion, contributes to attenuated inflammation and may slow pulmonary fibrosis progression. The article synthesizes findings from studies assessing rituximab\u2019s effects on lung function, clinical outcomes, and safety across distinct subtypes of connective tissue disease. It also discusses differential treatment responses based on disease characteristics and pathological subtypes, noting evidence that rituximab may be more effective as an initial treatment in some cases, though further investigation into long-term efficacy remains essential. Despite some associated risks, particularly infections, rituximab generally presents a favorable safety profile compared with conventional immunosuppressive therapies. Future research directions include optimizing dosing protocols, treatment intervals, and patient selection criteria, with emphasis on conducting rigorous, long-term randomized controlled trials to more definitively establish rituximab\u2019s role in managing interstitial lung disease in the context of connective tissue diseases.<\/jats:p>","DOI":"10.3389\/fmed.2025.1555442","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:12:46Z","timestamp":1747195966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review"],"prefix":"10.3389","volume":"12","author":[{"given":"Chenhao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zewei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4065\/82.8.976","article-title":"Diagnosis of interstitial lung diseases","volume":"82","author":"Ryu","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"17534666221117002","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single Centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1097\/MJT.0000000000001438","article-title":"Successful treatment of Sjogren-associated interstitial lung disease with rituximab","volume":"30","author":"Kesireddy","year":"2023","journal-title":"Am J Ther"},{"key":"ref10","first-page":"1077","article-title":"Rituximab therapy in primary Sj\u00f6gren's syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"Chen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.31138\/mjr.230323.cca","article-title":"Clinical characteristics and outcomes of interstitial lung disease in primary Sjogren's syndrome: a retrospective cohort study","volume":"35","author":"Manikuppam","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2020.08.004","article-title":"Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression","volume":"50","author":"Narvaez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"ref15","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with Antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- Synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1445-5994.2006.01055.x","article-title":"Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports","volume":"36","author":"Lim","year":"2006","journal-title":"Intern Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00296-020-04545-0","article-title":"Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data","volume":"40","author":"Robles-Perez","year":"2020","journal-title":"Rheumatol Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/diagnostics13071221","article-title":"Efficacy and safety of Nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single center experience","volume":"13","author":"Boutel","year":"2023","journal-title":"Diagnostics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10067-025-07323-0","article-title":"Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study","volume":"44","author":"M\u0131s\u0131rc\u0131","year":"2025","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41927-024-00400-y","article-title":"Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study","volume":"8","author":"Ushio","year":"2024","journal-title":"BMC Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"00481","DOI":"10.1183\/23120541.00481-2021","article-title":"Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease","volume":"8","author":"Boustani","year":"2022","journal-title":"ERJ Open Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.jaut.2021.102661","article-title":"Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease","volume":"121","author":"Takeshita","year":"2021","journal-title":"J Autoimmun"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2018.11.008","article-title":"Regulatory and effector B cells: friends or foes?","volume":"93","author":"Matsushita","year":"2019","journal-title":"J Dermatol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1165\/rcmb.2020-0387OC","article-title":"Antifibrotics modify B-cell-induced fibroblast migration and activation in patients with idiopathic pulmonary fibrosis","volume":"64","author":"Ali","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cyto.2014.11.008","article-title":"The cytokines of pulmonary fibrosis: much learned, much more to learn","volume":"74","author":"Luzina","year":"2015","journal-title":"Cytokine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31138\/mjr.33.1.1","article-title":"B cell depletion treatment in resistant systemic sclerosis interstitial lung disease","volume":"33","author":"Bounia","year":"2022","journal-title":"Mediterr J Rheumatol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/rheumatology\/keac578","article-title":"The role of B cells in the pathogenesis of systemic sclerosis: an update","volume":"62","author":"Sakkas","year":"2023","journal-title":"Rheumatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40674-020-00160-z","article-title":"Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment","volume":"6","author":"Huang","year":"2020","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11926-024-01155-8","article-title":"Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): update on prevalence, risk factors, pathogenesis, and therapy","volume":"26","author":"Sullivan","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10067-020-05320-z","article-title":"Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management","volume":"40","author":"Dai","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41584-020-00567-x","article-title":"New insights into the treatment of CTD-ILD","volume":"17","author":"Wells","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1183\/16000617.0011-2016","article-title":"Pulmonary manifestations of Sj\u00f6gren's syndrome","volume":"25","author":"Flament","year":"2016","journal-title":"Eur Respir Rev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/jcm12103428","article-title":"Primary-Sj\u00f6gren's-syndrome-related interstitial lung disease: a clinical review discussing current controversies","volume":"12","author":"La Rocca","year":"2023","journal-title":"J Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/BOR.0000000000000904","article-title":"Scleroderma autoantibodies in guiding monitoring and treatment decisions","volume":"34","author":"Shah","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-8-8","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review","volume":"10","author":"Cassone","year":"2021","journal-title":"Drugs Context"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10067-022-06404-8","article-title":"Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China","volume":"42","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive Fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1555442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:12:47Z","timestamp":1747195967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1555442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1555442"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1555442","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1555442"}}